Ionis Pharmaceuticals (Nasdaq: IONS) and AstraZeneca announced that the CARDIO-TTRansform Phase 3 trial of eplontersen in patients with transthyretin-mediated amyloid ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE